Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Analyst Upgrades and Downgrades

JAZZ has been the subject of several analyst reports. Piper Sandler reduced their price objective on shares of Jazz Pharmaceuticals from $197.00 to $193.00 in a research note on Thursday, May 5th. StockNews.com raised shares of Jazz Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday. HC Wainwright cut their target price on shares of Jazz Pharmaceuticals from $210.00 to $204.00 in a research report on Friday, August 5th. Cowen boosted their target price on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a research report on Thursday, May 5th. Finally, BMO Capital Markets boosted their price objective on shares of Jazz Pharmaceuticals from $185.00 to $188.00 and gave the stock an "outperform" rating in a report on Thursday, August 4th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $203.69.

Jazz Pharmaceuticals Trading Up 1.8 %

Jazz Pharmaceuticals stock traded up $2.83 during trading hours on Friday, hitting $157.08. 368,855 shares of the stock were exchanged, compared to its average volume of 510,241. The company has a debt-to-equity ratio of 1.87, a current ratio of 3.67 and a quick ratio of 2.45. Jazz Pharmaceuticals has a 12 month low of $117.64 and a 12 month high of $169.98. The business's 50-day moving average is $153.67 and its two-hundred day moving average is $152.30.

Insiders Place Their Bets

In other news, SVP Samantha Pearce sold 531 shares of the company's stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $155.00, for a total transaction of $82,305.00. Following the transaction, the senior vice president now directly owns 11,309 shares in the company, valued at $1,752,895. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Samantha Pearce sold 531 shares of the company's stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $155.00, for a total transaction of $82,305.00. Following the transaction, the senior vice president now directly owns 11,309 shares in the company, valued at $1,752,895. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 6,362 shares of the company's stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $146.87, for a total transaction of $934,386.94. Following the transaction, the chief executive officer now owns 351,987 shares in the company, valued at $51,696,330.69. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 48,093 shares of company stock valued at $7,436,900. 4.40% of the stock is currently owned by insiders.